Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial

被引：69

作者：

Feldman, SR

Kimball, AB

Krueger, GG

Woolley, JM

Lalla, D

Jahreis, A

机构：

[1] Wake Forest Univ, Bowman Gray Sch Med, Dept Dermatol, Winston Salem, NC 27157 USA

[2] Massachusetts Gen Hosp, Boston, MA 02114 USA

[3] Brigham & Womens Hosp, Boston, MA 02115 USA

[4] Utah Hlth Sci Ctr, Salt Lake City, UT USA

[5] Amgen Inc, Thousand Oaks, CA USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2005年 / 53卷 / 05期

关键词：

D O I：

10.1016/j.jaad.2005.06.053

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

In this randomized, double-blind, phase III trial, patients with psoriasis received etanercept for 24 weeks or placebo for 12 weeks followed by etanercept for 12 weeks. At week 12, improvement in Dermatology Life Quality Index was 47% to 61% with etanercept compared with 11% with placebo (P <.0001). Etanercept rapidly and substantially improved patients' health-related quality of life.

引用

页码：887 / 889

页数：3

共 13 条

[1]

[Anonymous], 2002, Br J Dermatol

[2] Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial [J].

Feldman, SR ;

Gordon, KB ;

Bala, M ;

Evans, R ;

Li, S ;

Dooley, LT ;

Guzzo, C ;

Patel, K ;

Menter, A ;

Gottlieb, AB .

BRITISH JOURNAL OF DERMATOLOGY, 2005, 152 (05) :954-960

[3] Quality of life assessments in dermatology [J].

Finlay, AY .

SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 1998, 17 (04) :291-296

[4] DERMATOLOGY LIFE QUALITY INDEX (DLQI) - A SIMPLE PRACTICAL MEASURE FOR ROUTINE CLINICAL USE [J].

FINLAY, AY ;

KHAN, GK .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1994, 19 (03) :210-216

[5]

Gupta MA, 1998, BRIT J DERMATOL, V139, P846

[6]

KIMBALL A, 2004, AM AC DERM SUMM AC M

[7] Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment [J].

Koo, J .

DERMATOLOGIC CLINICS, 1996, 14 (03) :485-&

[8] Etanercept as monotherapy in patients with psoriasis [J].

Leonardi, CL ;

Powers, JL ;

Matheson, RT ;

Goffe, BS ;

Zitnik, R ;

Wang, A ;

Gottlieb, AB ;

Bagel, J ;

Camisa, C ;

Caro, I ;

DiGiovanna, JJ ;

Dunlap, FF ;

Elewski, BE ;

Gribetz, CE ;

Farber, HF ;

Feldman, SR ;

Frankel, EH ;

Gaspari, AA ;

Goodman, JJ ;

Gordon, KB ;

Hampel, FC ;

Herdener, RS ;

Hoffman, MD ;

Humeniuk, JM ;

Johnson, SM ;

Kang, S ;

Kimball, AB ;

Kirsner, RS ;

Korman, NJ ;

Krueger, GG ;

Kuwahara, RT ;

Lebwohl, M ;

Ling, MR ;

Liu, DC ;

Lowe, N ;

McCall, CO ;

Menter, A ;

Miller, BH ;

Moore, JK ;

Nayak, AS ;

Ratner, PH ;

Savin, RC ;

Shupack, JL ;

Smith, SL ;

Stone, SP ;

Swinehart, JM ;

Taborn, J ;

Tschen, EH ;

Weinstein, GD ;

Werth, VP .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :2014-2022

[9]

Lundberg L, 2000, ACTA DERM-VENEREOL, V80, P430, DOI 10.1080/000155500300012873

[10] The application of multiple quality-of-life instruments in individuals with mild-to-moderate psoriasis [J].

Nichol, MB ;

Margolies, JE ;

Lippa, E ;

Rowe, M ;

Quell, J .

PHARMACOECONOMICS, 1996, 10 (06) :644-653

← 1 2 →